At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial
In Brief
A Phase 3 clinical trial evaluating Pegylated-interferon Alfa-2a and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 236 participants across 23 sites in 2 countries.
Detailed Summary
This study will compare the efficacy and safety of treatment with pegylated-interferon alfa-2a plus ribavirin in participants with non-genotype 2/3 CHC who, after 12 weeks of study treatment, have undetectable hepatitis C virus (HCV)-ribonucleic acid (RNA) or a greater than or equal to (\>=) 2 log10 drop in HCV-RNA. Participants will be randomized to receive pegylated-interferon alfa-2a 180 micrograms subcutaneously weekly plus ribavirin (1000-1400 milligram \[mg\]) orally daily for the specified duration, followed by 24 weeks of treatment-free follow-up. Participants with detectable HCV-RNA and less than (\<) 2 log10 drop in HCV-RNA at week 12 will discontinue therapy.
Study Details
Timeline
Interventions
Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.